Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques

Feliciana Real-Fernández, Francesca Pregnolato, Rolando Cimaz, Anna Maria Papini, Maria Orietta Borghi, Pier Luigi Meroni, Paolo Rovero

Research output: Contribution to journalArticle

Abstract

Reliable monitoring of clinical relevant anti-drug antibodies is fundamental in the follow-up of patients under adalimumab treatment. The aim of this study is to compare anti-adalimumab antibodies by using three methods based on different technologies. A cross-sectional study was performed in 50 patients with rheumatoid arthritis (RA) treated with adalimumab. Anti-adalimumab antibodies were detected in patients' sera by different techniques: bridging ELISA, reporter gene assay (RGA), and surface plasmon resonance (SPR). Results showed that all methods recognized anti-adalimumab antibodies and the percentage of positives fluctuated among the assays. Five (10%) of the 50 patients were positive in ELISA, 4 (8%) in RGA, and 6 (12%) in SPR. Among positive patients, 4 were positive in the three assays, one patient uniquely in ELISA, and two in SPR. Spearman correlation between ELISA and RGA showed good agreement (Spearman r = 0.800). No correlation between RGA and SPR was observed (Spearman r = 0.108). Similar results were obtained between ELISA and SPR (Spearman r = - 0.241). Summarizing, ELISA, RGA and SPR recognized anti-adalimumab antibodies in few RA patients, showing good agreement among the methodology employed. On the other hand, differences observed between SPR and ELISA or RGA highlight the relevance of the employed technologies in anti-drug antibody identification.

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalAnalytical Biochemistry
Volume566
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Surface Plasmon Resonance
Anti-Idiotypic Antibodies
Reporter Genes
Assays
Rheumatoid Arthritis
Surface plasmon resonance
Enzyme-Linked Immunosorbent Assay
Antibodies
Genes
Technology
Adalimumab
Pharmaceutical Preparations
Cross-Sectional Studies
Monitoring
Serum

Cite this

Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. / Real-Fernández, Feliciana; Pregnolato, Francesca; Cimaz, Rolando; Papini, Anna Maria; Borghi, Maria Orietta; Meroni, Pier Luigi; Rovero, Paolo.

In: Analytical Biochemistry, Vol. 566, 01.02.2019, p. 133-138.

Research output: Contribution to journalArticle

@article{358e24773b69451e927cab8d2717b3ee,
title = "Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques",
abstract = "Reliable monitoring of clinical relevant anti-drug antibodies is fundamental in the follow-up of patients under adalimumab treatment. The aim of this study is to compare anti-adalimumab antibodies by using three methods based on different technologies. A cross-sectional study was performed in 50 patients with rheumatoid arthritis (RA) treated with adalimumab. Anti-adalimumab antibodies were detected in patients' sera by different techniques: bridging ELISA, reporter gene assay (RGA), and surface plasmon resonance (SPR). Results showed that all methods recognized anti-adalimumab antibodies and the percentage of positives fluctuated among the assays. Five (10{\%}) of the 50 patients were positive in ELISA, 4 (8{\%}) in RGA, and 6 (12{\%}) in SPR. Among positive patients, 4 were positive in the three assays, one patient uniquely in ELISA, and two in SPR. Spearman correlation between ELISA and RGA showed good agreement (Spearman r = 0.800). No correlation between RGA and SPR was observed (Spearman r = 0.108). Similar results were obtained between ELISA and SPR (Spearman r = - 0.241). Summarizing, ELISA, RGA and SPR recognized anti-adalimumab antibodies in few RA patients, showing good agreement among the methodology employed. On the other hand, differences observed between SPR and ELISA or RGA highlight the relevance of the employed technologies in anti-drug antibody identification.",
author = "Feliciana Real-Fern{\'a}ndez and Francesca Pregnolato and Rolando Cimaz and Papini, {Anna Maria} and Borghi, {Maria Orietta} and Meroni, {Pier Luigi} and Paolo Rovero",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ab.2018.11.018",
language = "English",
volume = "566",
pages = "133--138",
journal = "Analytical Biochemistry",
issn = "0003-2697",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques

AU - Real-Fernández, Feliciana

AU - Pregnolato, Francesca

AU - Cimaz, Rolando

AU - Papini, Anna Maria

AU - Borghi, Maria Orietta

AU - Meroni, Pier Luigi

AU - Rovero, Paolo

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Reliable monitoring of clinical relevant anti-drug antibodies is fundamental in the follow-up of patients under adalimumab treatment. The aim of this study is to compare anti-adalimumab antibodies by using three methods based on different technologies. A cross-sectional study was performed in 50 patients with rheumatoid arthritis (RA) treated with adalimumab. Anti-adalimumab antibodies were detected in patients' sera by different techniques: bridging ELISA, reporter gene assay (RGA), and surface plasmon resonance (SPR). Results showed that all methods recognized anti-adalimumab antibodies and the percentage of positives fluctuated among the assays. Five (10%) of the 50 patients were positive in ELISA, 4 (8%) in RGA, and 6 (12%) in SPR. Among positive patients, 4 were positive in the three assays, one patient uniquely in ELISA, and two in SPR. Spearman correlation between ELISA and RGA showed good agreement (Spearman r = 0.800). No correlation between RGA and SPR was observed (Spearman r = 0.108). Similar results were obtained between ELISA and SPR (Spearman r = - 0.241). Summarizing, ELISA, RGA and SPR recognized anti-adalimumab antibodies in few RA patients, showing good agreement among the methodology employed. On the other hand, differences observed between SPR and ELISA or RGA highlight the relevance of the employed technologies in anti-drug antibody identification.

AB - Reliable monitoring of clinical relevant anti-drug antibodies is fundamental in the follow-up of patients under adalimumab treatment. The aim of this study is to compare anti-adalimumab antibodies by using three methods based on different technologies. A cross-sectional study was performed in 50 patients with rheumatoid arthritis (RA) treated with adalimumab. Anti-adalimumab antibodies were detected in patients' sera by different techniques: bridging ELISA, reporter gene assay (RGA), and surface plasmon resonance (SPR). Results showed that all methods recognized anti-adalimumab antibodies and the percentage of positives fluctuated among the assays. Five (10%) of the 50 patients were positive in ELISA, 4 (8%) in RGA, and 6 (12%) in SPR. Among positive patients, 4 were positive in the three assays, one patient uniquely in ELISA, and two in SPR. Spearman correlation between ELISA and RGA showed good agreement (Spearman r = 0.800). No correlation between RGA and SPR was observed (Spearman r = 0.108). Similar results were obtained between ELISA and SPR (Spearman r = - 0.241). Summarizing, ELISA, RGA and SPR recognized anti-adalimumab antibodies in few RA patients, showing good agreement among the methodology employed. On the other hand, differences observed between SPR and ELISA or RGA highlight the relevance of the employed technologies in anti-drug antibody identification.

U2 - 10.1016/j.ab.2018.11.018

DO - 10.1016/j.ab.2018.11.018

M3 - Article

VL - 566

SP - 133

EP - 138

JO - Analytical Biochemistry

JF - Analytical Biochemistry

SN - 0003-2697

ER -